This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Mar 20;375(9719):959-61.

doi: 10.1016/S0140-6736(10)60364-9.

Antisense technology to lower LDL cholesterol

R Dermot G Neely¹, Margaret F Bassendine

Affiliations

PMID: 20227757
DOI: 10.1016/S0140-6736(10)60364-9

Comment

Antisense technology to lower LDL cholesterol

R Dermot G Neely et al. Lancet. 2010.

. 2010 Mar 20;375(9719):959-61.

doi: 10.1016/S0140-6736(10)60364-9.

Authors

R Dermot G Neely¹, Margaret F Bassendine

Affiliation

¹ Clinical Biochemistry Department, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK. Dermot.Neely@nuth.nhs.uk

PMID: 20227757
DOI: 10.1016/S0140-6736(10)60364-9

No abstract available

PubMed Disclaimer

Comment on

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Raal FJ, et al. Lancet. 2010 Mar 20;375(9719):998-1006. doi: 10.1016/S0140-6736(10)60284-X. Lancet. 2010. PMID: 20227758 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

G0502028/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information